Department of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Division of Translational Medical Oncology, National Center for Tumor Diseases Heidelberg (NCT) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.
Eur Radiol. 2022 Dec;32(12):8617-8628. doi: 10.1007/s00330-022-08880-7. Epub 2022 Jun 9.
In the Cancer Core Europe Consortium (CCE), standardized biomarkers are required for therapy monitoring oncologic multicenter clinical trials. Multiparametric functional MRI and particularly diffusion-weighted MRI offer evident advantages for noninvasive characterization of tumor viability compared to CT and RECIST. A quantification of the inter- and intraindividual variation occurring in this setting using different hardware is missing. In this study, the MRI protocol including DWI was standardized and the residual variability of measurement parameters quantified.
Phantom and volunteer measurements (single-shot T2w and DW-EPI) were performed at the seven CCE sites using the MR hardware produced by three different vendors. Repeated measurements were performed at the sites and across the sites including a traveling volunteer, comparing qualitative and quantitative ROI-based results including an explorative radiomics analysis.
For DWI/ADC phantom measurements using a central post-processing algorithm, the maximum deviation could be decreased to 2%. However, there is no significant difference compared to a decentralized ADC value calculation at the respective MRI devices. In volunteers, the measurement variation in 2 repeated scans did not exceed 11% for ADC and is below 20% for single-shot T2w in systematic liver ROIs. The measurement variation between sites amounted to 20% for ADC and < 25% for single-shot T2w. Explorative radiomics classification experiments yield better results for ADC than for single-shot T2w.
Harmonization of MR acquisition and post-processing parameters results in acceptable standard deviations for MR/DW imaging. MRI could be the tool in oncologic multicenter trials to overcome the limitations of RECIST-based response evaluation.
• Harmonizing acquisition parameters and post-processing homogenization, standardized protocols result in acceptable standard deviations for multicenter MR-DWI studies. • Total measurement variation does not to exceed 11% for ADC in repeated measurements in repeated MR acquisitions, and below 20% for an identical volunteer travelling between sites. • Radiomic classification experiments were able to identify stable features allowing for reliable discrimination of different physiological tissue samples, even when using heterogeneous imaging data.
在癌症核心欧洲联盟(CCE)中,需要标准化的生物标志物来监测肿瘤多中心临床试验的治疗效果。与 CT 和 RECIST 相比,多参数功能 MRI,特别是扩散加权 MRI,在无创性肿瘤活力特征方面具有明显优势。在这种情况下,使用不同硬件进行的个体内和个体间变化的定量分析尚未进行。在这项研究中,我们对包括 DWI 在内的 MRI 方案进行了标准化,并对测量参数的剩余变异性进行了量化。
使用三个不同供应商生产的 MR 硬件,在七个 CCE 站点上进行了体模和志愿者测量(单次 T2w 和 DW-EPI)。在站点之间和站点之间(包括一位流动志愿者)进行了重复测量,比较了基于 ROI 的定性和定量结果,包括探索性放射组学分析。
对于使用中央后处理算法的 DWI/ADC 体模测量,最大偏差可降低至 2%。然而,与各自 MRI 设备上的分散 ADC 值计算相比,并没有显著差异。在志愿者中,2 次重复扫描的 ADC 测量变化不超过 11%,系统肝 ROI 中的单次 T2w 测量变化不超过 20%。站点之间的测量变化量对于 ADC 为 20%,对于单次 T2w 为<25%。探索性放射组学分类实验对 ADC 的分类结果优于单次 T2w。
MR 采集和后处理参数的协调一致,使得 MR/DW 成像的标准差达到可接受水平。MRI 可能是肿瘤多中心试验中的工具,可以克服基于 RECIST 的反应评估的局限性。
采集参数的协调和后处理的均匀化,使多中心 MR-DWI 研究的标准差达到可接受水平。
在重复 MR 采集的重复测量中,ADC 的总测量变化不超过 11%,而对于相同的志愿者在站点之间移动,ADC 的总测量变化不超过 20%。
即使使用异质成像数据,放射组学分类实验也能够识别出稳定的特征,从而能够可靠地区分不同的生理组织样本。